Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC6989-0001 · 1 trial · 2 indications
Measure in number of events.
Measured in number of events
Measured in ratio
| Arm | Type | Description |
|---|---|---|
| NNC6989-0001 | EXPERIMENTAL | Participants receive the investigational drug NNC6989-0001 |
| Placebo | PLACEBO_COMPARATOR | Participants receive placebo matched in appearance to the active drug. |
| Name | Type | Description |
|---|---|---|
| NNC6989-0001 | DRUG | Participants assigned to the active intervention receive NNC6989-0001 |
| Placebo (NNC6989-0001) | DRUG | Participants assigned to the placebo, receive placebo matched in appearance to the active drug. |
Inclusion Criteria: * Male or female of non-childbearing potential. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) (at screening) ≥ 25.0 and ≤ 34.9 kg/m\^2 for Part A (SAD part) and BMI (at screening) ≥ 25.0 and ≤ 39.9 kg/m\^2 for Part B (MAD...
NNC6989-0001 is an investigational small molecule being developed for the treatment of overweight and obesity. It is currently in Phase 1 clinical development, with a study enrolling healthy people living with overweight or obesity to evaluate its safety.
NNC6989-0001 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting a Phase 1 clinical trial to assess the safety of this investigational medicine.
NNC6989-0001 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 trial is currently recruiting participants to evaluate its safety in healthy individuals with overweight or obesity.
NNC6989-0001 is being studied in a Phase 1 clinical trial registered as NCT07437079. This randomized, double-blind, placebo-controlled study is recruiting 132 participants in the United States to assess the safety of the drug in healthy people living with overweight or obesity.
No alternative names for NNC6989-0001 have been identified. The drug is known by its code name NNC6989-0001 and is being developed by Novo Nordisk A/S for the treatment of overweight and obesity.